



## Flaviviruses: Immunity and Vaccine Development

Guest Editors:

### Dr. Wildriss Viranaicken

PIMIT, Processus Infectieux en  
Milieu Insulaire Tropical,  
Université de La Réunion,  
INSERM UMR 1187, CNRS 9192,  
IRD 249, Plateforme CYROI, 97490  
Sainte-Clotilde, Ile de La  
Réunion, France

### Dr. Pascale Krejbich

PIMIT, Processus Infectieux en  
Milieu Insulaire Tropical,  
Université de La Réunion,  
INSERM UMR 1187, CNRS 9192,  
IRD 249, Plateforme CYROI, 97490  
Sainte-Clotilde, Ile de La  
Réunion, France

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editors

Dear Colleagues,

The COVID pandemic is a reminder of how vulnerable the world's population is to zoonotic RNA viruses of medical concern. Among the viruses most likely to emerge and re-emerge is the arthropod-borne flavivirus family, which includes dangerous pathogens that currently infect hundreds of millions of people per year. The dengue virus (DENV), West Nile (WNV), yellow fever (YFV), Zika (ZIKV), Japanese encephalitis virus (JEV), tick-borne encephalitis virus (TBEV), and Usutu virus (USUV) are well-known members of the flavivirus family. They are responsible for a wide range of potentially serious visceral, neurotropic, and congenital diseases, as well as fetal death.

The purpose of this Special Issue, titled “Flavivirus: Immunity and Vaccine Development”, is to present the latest research results, hypothesis, and points of view on the field of flaviviruses–host interactions and conception of vaccine strategies. It is likely to be of interest to a wide range of translational researchers, virologists, cell and molecular biologists, physicians, etc.

Dr. Wildriss Viranaicken

Dr. Pascale Krejbich

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)